In 2019, researchers reported the first-ever human use of the senolytic combination dasatinib plus quercetin, in 14 patients with idiopathic pulmonary fibrosis. After three weeks of intermittent dosing, participants showed meaningful gains in 6-minute walk distance, gait speed and chair-stand time, even though lung function itself did not change. The pilot also logged one serious adverse event and frequent respiratory, skin and GI complaints. But this was an open-label, uncontrolled study of a cancer drug paired with a pharmacologic-dose flavonoid, not a supplement protocol. Here's what the trial actually tested, what it found, and how to read it critically.
This page is available in
